VRCA Quote, Financials, Valuation and Earnings

Corcept Therapeutics has a net margin of -283.28% compared to Verrica Pharmaceuticals's net margin of 13.07%. Verrica Pharmaceuticals's return on equity of -2619.46% beat Corcept Therapeutics's return on equity of 21.3%.

Verrica Pharmaceuticals has a consensus price target of $4.00, signalling upside risk potential of 665.4%. On the other hand Corcept Therapeutics has an analysts' consensus of $138.25 which suggests that it could grow by 88.82%. Given that Verrica Pharmaceuticals has higher upside potential than Corcept Therapeutics, analysts believe Verrica Pharmaceuticals is more attractive than Corcept Therapeutics.

Verrica Pharmaceuticals has a beta of 1.752, which suggesting that the stock is 75.233% more volatile than S&P 500. In comparison Corcept Therapeutics has a beta of 0.186, suggesting its less volatile than the S&P 500 by 81.38%.

Verrica Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Corcept Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Verrica Pharmaceuticals pays -- of its earnings as a dividend. Corcept Therapeutics pays out -- of its earnings as a dividend.

Verrica Pharmaceuticals quarterly revenues are $3.4M, which are smaller than Corcept Therapeutics quarterly revenues of $157.2M. Verrica Pharmaceuticals's net income of -$9.7M is lower than Corcept Therapeutics's net income of $20.5M. Notably, Verrica Pharmaceuticals's price-to-earnings ratio is -- while Corcept Therapeutics's PE ratio is 63.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verrica Pharmaceuticals is 4.65x versus 12.39x for Corcept Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Edgewise Therapeutics has a net margin of -283.28% compared to Verrica Pharmaceuticals's net margin of --. Verrica Pharmaceuticals's return on equity of -2619.46% beat Edgewise Therapeutics's return on equity of --.

Verrica Pharmaceuticals has a consensus price target of $4.00, signalling upside risk potential of 665.4%. On the other hand Edgewise Therapeutics has an analysts' consensus of $38.50 which suggests that it could grow by 192.33%. Given that Verrica Pharmaceuticals has higher upside potential than Edgewise Therapeutics, analysts believe Verrica Pharmaceuticals is more attractive than Edgewise Therapeutics.

Verrica Pharmaceuticals has a beta of 1.752, which suggesting that the stock is 75.233% more volatile than S&P 500. In comparison Edgewise Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Verrica Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edgewise Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Verrica Pharmaceuticals pays -- of its earnings as a dividend. Edgewise Therapeutics pays out -- of its earnings as a dividend.

Verrica Pharmaceuticals quarterly revenues are $3.4M, which are larger than Edgewise Therapeutics quarterly revenues of --. Verrica Pharmaceuticals's net income of -$9.7M is higher than Edgewise Therapeutics's net income of -$40.8M. Notably, Verrica Pharmaceuticals's price-to-earnings ratio is -- while Edgewise Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verrica Pharmaceuticals is 4.65x versus -- for Edgewise Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -283.28% compared to Verrica Pharmaceuticals's net margin of -49.65%. Verrica Pharmaceuticals's return on equity of -2619.46% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Verrica Pharmaceuticals has a consensus price target of $4.00, signalling upside risk potential of 665.4%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 40.31%. Given that Verrica Pharmaceuticals has higher upside potential than NovaBay Pharmaceuticals, analysts believe Verrica Pharmaceuticals is more attractive than NovaBay Pharmaceuticals.

Verrica Pharmaceuticals has a beta of 1.752, which suggesting that the stock is 75.233% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.427, suggesting its less volatile than the S&P 500 by 57.305%.

Verrica Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Verrica Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Verrica Pharmaceuticals quarterly revenues are $3.4M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Verrica Pharmaceuticals's net income of -$9.7M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Verrica Pharmaceuticals's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verrica Pharmaceuticals is 4.65x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

RxSight has a net margin of -283.28% compared to Verrica Pharmaceuticals's net margin of -21.61%. Verrica Pharmaceuticals's return on equity of -2619.46% beat RxSight's return on equity of -10.39%.

Verrica Pharmaceuticals has a consensus price target of $4.00, signalling upside risk potential of 665.4%. On the other hand RxSight has an analysts' consensus of $21.18 which suggests that it could grow by 67.18%. Given that Verrica Pharmaceuticals has higher upside potential than RxSight, analysts believe Verrica Pharmaceuticals is more attractive than RxSight.

Verrica Pharmaceuticals has a beta of 1.752, which suggesting that the stock is 75.233% more volatile than S&P 500. In comparison RxSight has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Verrica Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. RxSight offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Verrica Pharmaceuticals pays -- of its earnings as a dividend. RxSight pays out -- of its earnings as a dividend.

Verrica Pharmaceuticals quarterly revenues are $3.4M, which are smaller than RxSight quarterly revenues of $37.9M. Verrica Pharmaceuticals's net income of -$9.7M is lower than RxSight's net income of -$8.2M. Notably, Verrica Pharmaceuticals's price-to-earnings ratio is -- while RxSight's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verrica Pharmaceuticals is 4.65x versus 3.40x for RxSight. Usually stocks with elevated PS ratios are considered overvalued.